The combination of molecular-targeted agents with irradiation is a highly promising avenue
for cancer research and patient care. Molecular-targeted agents are in themselves not
curative in solid tumours, whereas radiotherapy is highly efficient in eradicating tumour stem
cells. Recurrences after high-dose radiotherapy are caused by only one or few surviving
tumour stem cells. Thus, even if a novel agent has the potential to kill only few tumour stem
cells, or if it interferes in mechanisms of radioresistance of tumours, combination with …